Yijun Pan

Personalising dosage regimens of medicines in Alzheimer's disease

Award: 
Dementia Australia Research Foundation Project Grant
Status: 
In Progress
Project Snapshot: 

Alzheimer’s disease is a medical condition affecting the brain. However, recent evidence suggests that our body is also affected by Alzheimer’s disease and as such, may absorb or metabolise medicines differently. Compared to those who do not have the disease, people living with Alzheimer’s disease tend to have more medical conditions and consume more medicines. Therefore, they are more likely to experience undesirable effects from medicine(s) or, as the body does not handle medicines in the same way as someone without Alzheimer’s disease, suffer the effects of under or overdosing. Prescribing practices can be improved if we understand what changes actually happen in our body when we have Alzheimer’s disease. Our project uses cutting-edge technology to thoroughly screen for the changes in a mouse model of Alzheimer’s disease as well as in human tissues. This information will be used to generate pharmacokinetic profiles of medications of interest. The profiles will promote medication safety and effectiveness in people with Alzheimer’s disease by helping doctors to decide the best treatment, with the least number of medicines, at the right dose.